Pioglitazone, an oral pill used for treating diabetes, has been linked to bladder cancer. The links have been controversial. Now, a new study sheds further light on this issue. The study, published in Diabetologia , a prestigious medical journal, assessed more than a million subjects in six countries. The study found no association between pioglitazone and bladder cancer. Bladder cancer is the ninth most common cancer worldwide, and is more common in people with diabetes as compared to those without diabetes. In this study, the authors did not find any relationship between the duration of exposure to pioglitazone and bladder cancer.
Pioglitazone, which makes the body's insulin work better, however, has many other side effects. These include cardiac failure, weight gain, body swelling and reduction of bone density.